ADAP Stock Overview
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Adaptimmune Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.87 |
| 52 Week High | US$3.32 |
| 52 Week Low | US$1.01 |
| Beta | 2.18 |
| 1 Month Change | 28.08% |
| 3 Month Change | 17.61% |
| 1 Year Change | -33.21% |
| 3 Year Change | -58.44% |
| 5 Year Change | -78.99% |
| Change since IPO | -89.15% |
Recent News & Updates
Recent updates
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14We Think Adaptimmune Therapeutics (NASDAQ:ADAP) Can Easily Afford To Drive Business Growth
Apr 15Investors Who Bought Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Are Now Up 101%
Mar 15Is Adaptimmune Therapeutics plc (NASDAQ:ADAP) Popular Amongst Institutions?
Feb 17
Have Adaptimmune Therapeutics plc (NASDAQ:ADAP) Insiders Been Selling Their Stock?
Jan 22Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business
Jan 15Adaptimmune Therapeutics (NASDAQ:ADAP) Shareholders Have Enjoyed An Impressive 227% Share Price Gain
Dec 11Shareholder Returns
| ADAP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.6% | -0.2% | 1.7% |
| 1Y | -33.2% | 3.9% | -12.5% |
Return vs Industry: ADAP underperformed the US Biotechs industry which returned 1.2% over the past year.
Return vs Market: ADAP underperformed the US Market which returned -13.6% over the past year.
Price Volatility
| ADAP volatility | |
|---|---|
| ADAP Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ADAP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: ADAP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 494 | Ad Rawcliffe | https://www.adaptimmune.com |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company’s specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers.
Adaptimmune Therapeutics plc Fundamentals Summary
| ADAP fundamental statistics | |
|---|---|
| Market Cap | US$306.36m |
| Earnings (TTM) | -US$175.06m |
| Revenue (TTM) | US$17.54m |
17.5x
P/S Ratio-1.7x
P/E RatioIs ADAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADAP income statement (TTM) | |
|---|---|
| Revenue | US$17.54m |
| Cost of Revenue | US$134.18m |
| Gross Profit | -US$116.64m |
| Other Expenses | US$58.42m |
| Earnings | -US$175.06m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | -665.12% |
| Net Profit Margin | -998.26% |
| Debt/Equity Ratio | 0% |
How did ADAP perform over the long term?
See historical performance and comparison